Edition:
United States

Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

2.10USD
4:00pm EDT
Change (% chg)

$0.12 (+6.06%)
Prev Close
$1.98
Open
$1.97
Day's High
$2.18
Day's Low
$1.97
Volume
126,907
Avg. Vol
288,144
52-wk High
$5.59
52-wk Low
$0.78

Latest Key Developments (Source: Significant Developments)

Aeterna Zentaris reports departure of finance and chief accounting officer
Friday, 1 Sep 2017 04:30pm EDT 

Sept 1 (Reuters) - Aeterna Zentaris Inc ::Aeterna Zentaris announces departure of vice president, finance & chief accounting officer.Aeterna Zentaris - ‍ departure of co's vice president, finance & chief accounting officer, Geneviéve Lemaire, effective on or before sept 30, 201​.Aeterna Zentaris Inc - ‍ commenced a search for Lemaire's replacement as principal financial officer​.  Full Article

Aeterna Zentaris reports Q2 loss per share $0.18
Thursday, 10 Aug 2017 06:09pm EDT 

Aug 10 (Reuters) - Aeterna Zentaris Inc -:Aeterna Zentaris reports second quarter 2017 financial and operating results.Q2 loss per share $0.18.Aeterna Zentaris Inc - ‍is conducting a strategic review of its plans​.Aeterna Zentaris Inc - ‍restructuring program of frankfurt, germany operations was approved by company and german work council​.Aeterna Zentaris Inc - ‍total cost of restructuring program is expected to be approximately $2.0 million​.Aeterna Zentaris Inc - ‍most of restructuring costs are expected to be paid in financial year ending december 31, 2018​.Aeterna Zentaris-‍formed special committee of independent directors to consider & evaluate various strategic and financing alternatives available to co.Aeterna Zentaris Inc - ‍three sales representatives and one sales-manager position were eliminated at quarter-end as part of sales force optimization​.Aeterna Zentaris Inc- ‍goal is to be prepared to launch macrilen in united states in q1 of 2018​.Aeterna Zentaris-restructuring program should lead to annual savings of about $2.5 million following complete implementation expected to be at end of 2018​.  Full Article

David Dodd responds to claim filed by Aeterna Zentaris
Friday, 4 Aug 2017 02:47pm EDT 

Aug 4 (Reuters) - David Dodd::David Dodd, former CEO of Aeterna Zentaris, responds to claim filed by Aeterna Zentaris against him & Philip Theodore​.Says intends to continue to serve as director of Aeterna.Says Dodd and Theodore consider Aeterna's claim to be "without merit", and intend to defend against it​.  Full Article

Aeterna Zentaris says ‍strategic review committee will be chaired by Carolyn Egbert, and includes Michael Cardiff​
Thursday, 20 Jul 2017 05:00pm EDT 

July 20 (Reuters) - Aeterna Zentaris Inc :Aeterna Zentaris forms strategic review committee and appoints Michael Ward as CEO.Aeterna Zentaris Inc - ‍Strategic review committee will be chaired by Carolyn Egbert, and includes Michael Cardiff​.David A. Dodd has ceased to be company's president and CEO with immediate effect..Board of directors of company has appointed Michael Ward as company's chief executive officer.Aeterna Zentaris Inc - ‍Formed a special committee to consider and evaluate various strategic and financing alternatives available to company​.Aeterna Zentaris Inc - ‍Special committee to evaluate alternatives including considering and recommending changes to co's management and governance​.  Full Article

Aeterna Zentaris resubmits NDA for Macrilen for the evaluation of growth hormone deficiency in adults
Friday, 30 Jun 2017 09:15am EDT 

June 30 (Reuters) - Aeterna Zentaris Inc :Aeterna Zentaris resubmits NDA for Macrilen™ for the evaluation of growth hormone deficiency in adults.Aeterna Zentaris - "Believe FDA review period of NDA will be up to 6 months, setting stage for potential approval of product late in 2017, early in 2018".Aeterna Zentaris Inc - Focus is to be prepared to launch Macrilen in Q1 of 2018.  Full Article

Aeterna Zentaris qtrly loss per share $0.31
Monday, 8 May 2017 04:30pm EDT 

May 8 (Reuters) - Aeterna Zentaris Inc ::Aeterna Zentaris reports first quarter 2017 financial and operating results.Aeterna Zentaris Inc - qtrly revenue $261,000 versus $242,000; qtrly loss per share $0.31.Aeterna Zentaris Inc - do not anticipate conducting clinical trials of zoptrex with respect to any other indications.Aeterna Zentaris Inc - co's focus has now shifted entirely to filing new drug application for macrilen.  Full Article

Aeterna Zentaris says ZoptEC Phase 3 clinical study of Zoptrex did not achieve primary endpoint
Monday, 1 May 2017 08:00am EDT 

May 1 (Reuters) - Aeterna Zentaris Inc :Aeterna Zentaris announces that ZoptEC Phase 3 clinical study of Zoptrex did not achieve its primary endpoint.Aeterna Zentaris Inc - company expects to submit Macrilen NDA in Q3 of 2017.Aeterna Zentaris Inc - Zoptrex generally performed no better than comparator drug with respect to secondary efficacy endpoints.Aeterna Zentaris - median overall survival period for patients treated with Zoptrex was 10.9 months which is not a statistically significant.Aeterna Zentaris - intention to submit Macrilen NDA in Q3 of 2017 and, if product receives FDA approval, to commercially launch product in Q1 of 2018.  Full Article

Aeterna Zentaris files for common shares stock shelf offering of up to $50 mln
Tuesday, 21 Mar 2017 04:49pm EDT 

Aeterna Zentaris Inc :Aeterna Zentaris Inc- files for common shares stock shelf offering of up to $50 million - sec filing.  Full Article

Aeterna Zentaris qtrly loss per share $0.71
Wednesday, 15 Mar 2017 04:48pm EDT 

Aeterna Zentaris Inc : Aeterna Zentaris reports fourth quarter and full-year 2016 financial and operating results .Aeterna Zentaris Inc - qtrly loss per share $0.71.  Full Article

Aeterna Zentaris announces EMA pediatric committee agreement
Tuesday, 7 Mar 2017 08:30am EST 

Aeterna Zentaris Inc : Aeterna Zentaris announces EMA pediatric committee agreement on the pediatric investigation plan for macrilen(TM) . Aeterna Zentaris Inc- .Aeterna Zentaris - pediatric committee of EMA agreed co may defer conducting pip until after it files a MAA seeking authorization for use of Macrilen.  Full Article

BRIEF-Altitude Resources says Kuro Coal to acquire 100 pct interest in Elan coal project

* Altitude resources inc - entered into a share sale deed under which Kuro coal Canada will purchase 100% of Elan coal ltd